|
Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price Investor's Business DailyNovo Nordisk to Replace C.E.O. After Losing Edge in Weight-Loss Drugs The New York TimesOzempic CEO's Exit From Novo Started With Teams Call Surprise BloombergNovo Nordisk: CEO's Surprise Departure Points to Challenging Obesity Market Dynamics Morningstar
|
|
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight years in the role, the maker of Ozempic and Wegovy drugs announced on Friday.
|
|
